Skip to content
Family HoldingPuts its own capital into companiesActive · deal in last 18 monthsLAST VERIFIED Oct 2026 · 6 SOURCES

Angelini Holding

Also known as Angelini Holding S.p.A., Angelini Industries, Gruppo Angelini

Rome holding of the Angelini group (Angelini Industries); via Angelini Investments it holds 10.6% of TIP; the group’s CVC is Angelini Ventures.

USEFUL FOR Co-investors

Rome holding company of the Angelini group (Angelini Industries); its financial-investment company is Angelini Investments S.r.l. and the group’s CVC is Angelini Ventures.

Family & background

FAMILY
Angelini
WEALTH ORIGIN
Pharmaceuticals (Angelini Pharma / A.C.R.A.F.)
HEADQUARTERS
Rome, Italy
OUTSIDE CAPITAL
No — own capital only

Investment approach

SECTORS
Biotech & Life SciencesHealthTech
GEOGRAPHY
ItalyGlobal
ROUTES
Companies (own capital)
STRATEGIES
Direct investmentsVenture capitalPublic equities
LATEST DEAL
Aptadir Therapeutics (€40M seed round led by 4BIO Capital; direct investment by Angelini Ventures (group CVC)) · Sep 2026

Overview

Angelini Holding S.p.A. is a Rome holding company of the Angelini group whose direct subsidiaries in the GLEIF register include Angelini Pharma Italia (A.C.R.A.F.) and Angelini Investments S.r.l. Its subsidiary Angelini Investments S.r.l., the group’s financial company, holds 10.596% of Tamburi Investment Partners. Angelini Ventures, launched in 2022, is the group’s corporate venture capital arm; in 2026 it invested in Handspring (Series B) and Aptadir Therapeutics (seed). CONSOB lists Thea Paola Angelini at the top of the control chain of the TIP stake.

Holdings & investments (4)

INVESTMENT ARMS & VEHICLES

  • Angelini Investments S.r.l.
    Financial-investment company of the group (direct child of Angelini Holding in GLEIF); holds the TIP stake
  • Angelini Ventures
    Corporate venture capital arm of Angelini Industries, launched 2022 with a €300M allocation (biotech, medtech, digital health)

HOLDINGS & INVESTMENTS · MOST RECENT FIRST

Frequently asked questions

Angelini Holding is a family holding based in Rome, Italy.

Angelini Holding invests on behalf of the Angelini family (Pharmaceuticals (Angelini Pharma / A.C.R.A.F.)).

Angelini Holding invests its own capital into companies. Its stated asset mix includes direct investments, venture capital and public equities.

Angelini Holding invests in Biotech & Life Sciences and HealthTech.

Angelini Holding's holdings and investments include Angelini Pharma S.p.A. (A.C.R.A.F.), Tamburi Investment Partners (10.596%, via Angelini Investments), Aptadir Therapeutics (via Angelini Ventures) and Handspring Health (via Angelini Ventures).

The most recent publicly reported investment by Angelini Holding is Aptadir Therapeutics (€40M seed round led by 4BIO Capital; direct investment by Angelini Ventures (group CVC)), announced in Sep 2026.

No. Angelini Holding invests its own capital and does not raise money from outside investors.